Youtor
Stephen Stahl Future of Psychopharmacology Is New Treatment Innovation “Dead”
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=307vwmlTkwM
Watch on LabRoots at http://labroots.com/webcast/id/816 • Adjunct Professor of Psychiatry, University of California, San Diego, Honorary Visiting Senior Fellow, University of Cambridge, UK, Chairman, Neuroscience Education Institute (NEI), Editor-in Chief, CNS Spectrums, Director of Psychopharmacology Services, California Department of State Hospitals • Innovation in Psychopharmacology is Dead. Long Live Innovation in Psychopharmacology! • What’s going on in our field? • Priorities of Big Pharma shifting away from CNS and especially from psychiatry • Failed clinical trials littering the landscape • Even known drugs don’t work in psychiatric trials • Broken clinical trial apparatus • Iterative step-wise improvements or ‘me-too’ agents not reimbursed • Aggressive cost controls • No new validated targets • Learning objectives - • Discuss the reasons for the slow down of innovative new treatments entering psychopharmacology and the exit of Big Pharma largely from psychiatry • Show that future advances may be based on targeting symptoms that cut across a large array of psychiatric disorders • Propose that effective new treatments will be based upon subpopulations defined mostly in the short run by symptoms but in the long run by genetic and imaging biomarkers
#############################
